Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.46 |
| ▸ | CFB | P00751 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3890628 | 0.89 | CFB (0.47) | CFBSIGMAR1GBA1 | |
| SCHEMBL3894111 | 0.84 | GRIN2B (0.46) | DRD2DRD4PAX8CFBSIGMAR1 | |
| SCHEMBL3890565 | 0.82 | LMNA (0.40) | DRD2DRD4PAX8CFBMAOA | |
| SCHEMBL3893163 | 0.80 | GBA1 (0.43) | CFBSIGMAR1GBA1MAOAMAOB | |
| SCHEMBL6497571 | 0.80 | CFB (0.47) | DRD2DRD4CFBSIGMAR1GBA1 | |
| SCHEMBL6042431 | 0.78 | CFB (0.47) | CFBSIGMAR1GBA1RORC | |
| SCHEMBL3901486 | 0.76 | NPC1 (0.45) | CFBGBA1KDM1A | |
| SCHEMBL3899665 | 0.75 | PAX8 (0.42) | PAX8CFBGRIN2BMAOAMAOB | |
| SCHEMBL30768210 | 0.72 | MEN1 (0.50) | CFBMAOBKDM1A | |
| SCHEMBL21625238 | 0.72 | MEN1 (0.50) | CFBMAOBKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642262-B2 | Arylipiperdinopropanol and arylipiperazinopropanol derivatives and pharmaceuticals containing the same | ASUBIO PHARMA CO., LTD. (JP) | 2010-01-05 | — | — | US | disclosed |
| US-7498344-B2 | Arylpiperidinol and arylpiperidine derivatives and pharmaceuticals containing the same | ASUBIO PHARMA CO., LTD. (JP) | 2009-03-03 | — | — | US | disclosed |
| US-20050101610-A1 | Arylipiperdinopropanol and arylipiperazinopropanol derivatives and pharmaceuticals containing the same | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-0958280-B1 | ARYLPIPERIDINOPROPANOL AND ARYLPIPERAZINOPROPANOL DERIVATIVES AND PHARMACEUTICALS CONTAINING THE SAME | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2005-05-04 | — | — | EP | disclosed |
| US-6838470-B2 | Arylpiperidinopropanol and arylpiprazinopropanol derivatives and pharmaceuticals containing the same | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-01-04 | — | — | US | disclosed |
| EP-0867183-B1 | ARYLPIPERIDINOL AND ARYLPIPERIDINE DERIVATIVES AND DRUGS CONTAINING THE SAME | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2004-10-06 | — | — | EP | disclosed |
| US-20040186138-A1 | Arylpiperidinol and arylpiperidine derivatives and pharmaceuticals containing the same | DAIICHI SUNTORY PHARMA CO., LTD. | 2004-09-23 | — | — | US | disclosed |
| US-6706734-B2 | ANTIISCHEMIC AGENTS; ANTICONVULSANTS; HEADACHES | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2004-03-16 | — | — | US | disclosed |
| US-20030236269-A1 | Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same | ASUBIO PHARMA CO., LTD. (JP) | 2003-12-25 | — | — | US | disclosed |
| US-20030130312-A1 | Arylpiperidinol and arylpiperidine derivatives and pharmaceuticals containing the same | ASUBIO PHARMA CO., LTD. (JP) | 2003-07-10 | — | — | US | disclosed |
| US-6525199-B1 | Ring coupling, reduction and deprotecting; synthesis of compounds for alleviation and treatment of symptoms due to ischemic diseases | SUNTORY LIMITED (JP) | 2003-02-25 | — | — | US | disclosed |
| US-6455549-B1 | ANTIEPILEPTIC, ANTIISCHEMIC, AND ANTIMIGRAINE AGENTS; CALCIUM OVELOAD SUPPRESSANTS | SUNTORY LIMITED (JP) | 2002-09-24 | — | — | US | disclosed |
| US-6407099-B1 | SUPPRESSING CYTOTOXIC CALCIUM OVERLOAD AND LIPID PEROXIDATION; ANTIEPILEPTIC, ANTIISCHEMIC, AND ANTIEDEMIC AGENTS; BRAIN, NERVOUS SYSTEM, AND CARDIOVASCULAR DISORDERS | SUNTORY LIMITED (JP) | 2002-06-18 | — | — | US | disclosed |
| EP-1138678-A2 | Process for making N-((4-phenyl) methylphenyl) piperazines | SUNTORY LIMITED (JP) | 2001-10-04 | — | — | EP | disclosed |
| EP-0867183-A1 | ARYLPIPERIDINOL AND ARYLPIPERIDINE DERIVATIVES AND DRUGS CONTAINING THE SAME | SUNTORY LIMITED (JP) | 1998-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130312-A1 | Arylpiperidinol and arylpiperidine derivatives and pharmaceuticals containing the same | KCNH1, KCNH2, NPY1R | DRD2 2055/4885DRD4 3344/4885PAX8 2609/4885 |
| US-20030236269-A1 | Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same | NR1H2, NR1H3, APOL1 | DRD2 2441/4885DRD4 2370/4885PAX8 2341/4885 |
| US-20050101610-A1 | Arylipiperdinopropanol and arylipiperazinopropanol derivatives and pharmaceuticals containing the same | NR1H2, NR1H3, NR3C2 | DRD2 1034/4885DRD4 1244/4885PAX8 1430/4885 |
| US-20040186138-A1 | Arylpiperidinol and arylpiperidine derivatives and pharmaceuticals containing the same | KCNH1, KCNH2, NPY1R | DRD2 2055/4885DRD4 3344/4885PAX8 2609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.